Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular disease

•1070 patients with hyperuricemia were randomized to febuxostat or non-febuxostat treatment.•Patients with hyperuricaemia and CVD had an increased risk for cardiovascular events.•Fewer CV events and all-cause death were observed in febuxostat group than non-febuxostat group.